Entheon Biomedical Corp.

CNSX: ENBI


Canadian symbol: ENBI.CN
US symbol: ENTBF

Currency in CAD

Valuation Measures

Market Cap (intraday) 521.62M
Enterprise Value 313.55M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)1.63
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 7-3.10

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3-13.10%
S&P500 52-Week Change 343.61%
52 Week High 31.3500
52 Week Low 30.3000
50-Day Moving Average 30.5443
200-Day Moving Average 30.7347

Share Statistics

Avg Vol (3 month) 3219.56k
Avg Vol (10 day) 3180.74k
Shares Outstanding 554.04M
Implied Shares Outstanding 6N/A
Float 42.56M
% Held by Insiders 19.33%
% Held by Institutions 12.22%
Shares Short (Apr. 14, 2021) 449k
Short Ratio (Apr. 14, 2021) 40.28
Short % of Float (Apr. 14, 2021) 4N/A
Short % of Shares Outstanding (Apr. 14, 2021) 40.12%
Shares Short (prior month Mar. 14, 2021) 454.03k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:3
Last Split Date 3Nov. 11, 2020

Financial Highlights

Fiscal Year

Fiscal Year Ends Nov. 29, 2020
Most Recent Quarter (mrq)Feb. 27, 2021

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)N/A
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -4.37M
Net Income Avi to Common (ttm)-6.9M
Diluted EPS (ttm)-0.2040
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)5.02M
Total Cash Per Share (mrq)0.1
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)37.53
Book Value Per Share (mrq)0.25

Cash Flow Statement

Operating Cash Flow (ttm)-5.23M
Levered Free Cash Flow (ttm)N/A

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Psychedelics News and Psilocybin Investing

Real-time news from hundreds of sources. Never miss the news that matters the most.




Company News Date

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
9.33%% of Shares Held by All Insider
2.22%% of Shares Held by Institutions
2.45%% of Float Held by Institutions
2Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Entheon Biomedical Corp.


Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development

Vancouver, British Columbia--(Newsfile Corp. - January 19, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTC Pink: ENTBF) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced a partnership with Divergence Neuro Technologies Inc. ("Divergence"), a compan... Read More...

Entheon Biomedical Engages World Renowned Media Personality DJ Skee, AKA Scott Keeney, as Media Advisor

Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has engaged Mr. Scott Keeney, to serve as a media advisor.In his role, Mr. ... Read More...

Entheon Biomedical Announces Investment and Business Arrangement with Heading Health LLC

Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is announcing a business arrangement with, and a strategic investment in, Heading Health, LLC ("Heading Hea... Read More...

Entheon Biomedical Closes Private Placement

Vancouver, British Columbia--(Newsfile Corp. - December 25, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company") announces that it has closed a non-brokered private placement financing for total gross proceeds of CAD $3,174,374.25 (the "Placement"). The majority of the Placement was subscribed for by strat... Read More...

Entheon Biomedical Announces Private Placement

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2020) - Β Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company") announces that it is proceeding with a fully allocated, non-brokered private placement financing of 4,266,997 Units (the "Units") at a price of CDN$0.75 per Unit for gross proceeds of CDN$3,200... Read More...

Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants

Vancouver, British Columbia--(Newsfile Corp. - December 9, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the "Agreement") with Psygen Labs Inc. ("Psygen"). ... Read More...

Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces a strategic investment in Wonder Scientific Inc. ("Wonder Scientific").Wonder Scientific's team ... Read More...

Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021

Vancouver, British Columbia--(Newsfile Corp. - December 1, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a Clinical Study Agreement with the Contract Research Organization (CRO) Cen... Read More...
Coming Soon.

Delayed data (1h)


Share this page